The city of Nashville, Tennessee, currently has 3 active clinical trials seeking participants for Healthy research studies.
Swallowing Impairments in Adults With and Without Alzheimer's Disease
Recruiting
This research study is investigating whether people with Alzheimer's disease (AD) experience more changes to swallowing than their healthy age-matched peers. The prevalence of swallowing impairments in moderate-severe AD is high (85-93%), yet little is known about how swallow function evolves throughout the disease course in people with AD. The overall objective of this study is to evaluate swallowing function in adults with and without Alzheimer's disease. The investigator will also be involvin... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
03/10/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Alzheimer Disease, Caregiver Burden, Healthy Aging, Dysphagia
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals
Recruiting
Pulmonary arterial hypertension (PAH) is a severe disease with a delayed diagnosis and markedly elevated mortality. High-risk populations, such as those with known genetic defects, provide a unique opportunity to determine the features of susceptibility and resilience to PAH. This proposal will fundamentally overturn the prevailing understanding of PAH by creating molecularly-driven signatures of susceptibility and resilience, provide novel insight into disease severity, and potentially identify... Read More
Gender:
ALL
Ages:
Between 15 years and 80 years
Trial Updated:
02/14/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo, Healthy Individuals With no Cardiopulmonary Disease
A Phase 1, Dose-Escalation, Positron Emission Tomography Study to Assess the Safety, Pharmacokinetics, Dosimetry and Biodistribution of GEH200521 (18F) Injection Co-Administered With GEH200520 Injection in Healthy Volunteers
Recruiting
This is a Phase 1, single-center, open-label, single-arm, dose-escalation positron emission tomography study to assess the safety and tolerability, immunogenicity, Pharmacokinetics, dosimetry, and biodistribution after GEH200521 (18F) Injection is co-administered with GEH200520 Injection in healthy volunteers. The estimated study duration for each subject is approximately 28 days. The primary study objective is to evaluate the safety and tolerability of the IMPs, the selected mass doses of GEH... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Healthy Volunteers